Trial Profile

An Open-Label Extension Study of Continuing Treatment With Trofinetide for Rett Syndrome

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 07 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Trofinetide (Primary)
Indications Rett syndrome
Focus Adverse reactions
Acronyms LILAC-2
Sponsors Acadia Pharmaceuticals

Most Recent Events

05 Mar 2025 According to an Acadia Pharmaceuticals media release, results of DAFFODIL, LAVENDER, LILAC-1 and LILAC-2 studies supported the FDA approval of DAYBUE in adults and pediatric patients two years of age or older.
27 Sep 2024 Status changed to discontinued.
06 Aug 2024 According to Acadia media release, the journal Med published clinical data from two open-label extension studies, LILAC-1 and LILAC-2.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com